ConductScience.org, home

Paper30716481

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.

Kumar P and 2 others. Semin Cancer Biol, 2020. Cited by 101 papers, by iCite.

Cite this record

ConductScience Library. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis. Papers, record 30716481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30716481

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
PubMed
Journal
Semin Cancer Biol
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
101
iCite
Relative citation ratio, by iCite
4.1
iCite
Revised in PubMed
2020-12-14
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kumar PPrabhakaran
2Saini SShikha
3Prabhakar BSBellur S

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, ImmunologicalMajor topic
Autoimmune DiseasesMajor topic
ImmunotherapyMajor topic
NeoplasmsMajor topic
T-Lymphocytes, RegulatoryMajor topic
Tumor MicroenvironmentMajor topic
Animals
B7-H1 Antigen
CTLA-4 Antigen
Homeostasis
Humans

Source PubMed

Download CSV of topics

Cited by80

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 101 citations.

PMIDTitleJournalYearIn PapersSource
42982819The chromatin-organizer Satb1 modulates regulatory T cell activity within the tumor microenvironment.Nat Commun2026https://conductscience.org/library/papers/42982819PubMed
42960125Mechanisms of Resistance and Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Narrative Review.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42960125PubMed
42908539Clinicopathologic characteristics and diagnostic value of PD-L1 in immune checkpoint inhibitor-related liver injury: a single-center retrospective study.Front Oncol2026https://conductscience.org/library/papers/42908539PubMed
42769860From mechanisms to practice: risk management and multidisciplinary decision-making for systemic treatment-related liver injury in HBV-associated hepatocellular carcinoma.Front Pharmacol2026https://conductscience.org/library/papers/42769860PubMed
42688372Recruited Monocyte-Derived Macrophages Drive T Cell Inflammation in Immune Checkpoint Inhibitor-Mediated Pneumonitis.Cancer Commun (Lond)2026https://conductscience.org/library/papers/42688372PubMed
42653263Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review.Int J Mol Sci2026https://conductscience.org/library/papers/42653263PubMed
42421963Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study.Front Immunol2026https://conductscience.org/library/papers/42421963PubMed
41988173Integrated risk stratification for ICI-associated myocarditis: a baseline hematological profile and a combined ECG and enzymatic signature at onset.Front Immunol2026https://conductscience.org/library/papers/41988173PubMed
41972182Reversing chemoresistance in ovarian cancer: network pharmacology reveals how hydroxychloroquine/sulfasalazine duotherapy remodels tumor inflammatory-immune microenvironment.Front Immunol2026https://conductscience.org/library/papers/41972182PubMed
41836384Single-cell profiling of PBMCS reveals an immune signature of irAEs in anti-PD-1-treated acral melanoma patients.Front Immunol2026https://conductscience.org/library/papers/41836384PubMed
41306369Consensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024).J Clin Transl Hepatol2025https://conductscience.org/library/papers/41306369PubMed
41026295Role of interleukin-6 in resistance to tumor therapy.Discov Oncol2025https://conductscience.org/library/papers/41026295PubMed
40842015Biomechanics of the tumor extracellular matrix and regulatory T cells: regulatory mechanisms and potential therapeutic targets.Cell Commun Signal2025https://conductscience.org/library/papers/40842015PubMed
40267151Pan-cancer analysis and validation show GTF2E2's diagnostic, prognostic, and immunological roles in regulating ferroptosis in endometrial cancer.PLoS One2025https://conductscience.org/library/papers/40267151PubMed
40071935Structural investigation of an RNA device that regulates PD-1 expression in mammalian cells.Nucleic Acids Res2025https://conductscience.org/library/papers/40071935PubMed
40051755The immunopeptidome of colon cancer cells treated with topoisomerase inhibiting drug reveals differential as well as common endogenous protein sampling and display of MHC I-associated peptides.Mol Cell Oncol2025https://conductscience.org/library/papers/40051755PubMed
39868913Immune-Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges.Liver Int2025https://conductscience.org/library/papers/39868913PubMed
39832113Pan-cancer analysis and single-cell analysis identifies the CENPN as a biomarker for survival prognosis and immunotherapy.Discov Oncol2025https://conductscience.org/library/papers/39832113PubMed
39788584[Consensus on the management of liver injury associated with targeted drugs and immune checkpoint inhibitors for hepatocellular carcinoma ( version 2024)].Zhonghua Gan Zang Bing Za Zhi2024https://conductscience.org/library/papers/39788584PubMed
39719469Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.Med Oncol2024https://conductscience.org/library/papers/39719469PubMed

See all 80 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30716481

GET https://conductscience.org/api/papers/v1/30716481/cited_by?page=2